ARTICLE | Emerging Company Profile
Mimetogen: An eye for neuroprotection
September 17, 2007 7:00 AM UTC
Mimetogen Pharmaceuticals Inc. believes it is the first company attempting to treat glaucoma and other degenerative ophthalmic diseases through neuroprotection, an approach it expects would complement existing drugs.
The company's lead compound mimics the pro-survival effects that nerve growth factor (NGF) has on retinal cells. A second program targets a neurotoxic protein that is up-regulated in response to high intraocular pressure and is a novel target in the pathology of vision-impairing cell loss. ...